<DOC>
	<DOCNO>NCT02516241</DOCNO>
	<brief_summary>A Phase III , Randomized , Open-Label , Controlled , Multi-Center , Global Study First-Line MEDI4736 Monotherapy MEDI4736 Combination Tremelimumab Versus Standard Care Chemotherapy Patients Stage IV Urothelial Cancer</brief_summary>
	<brief_title>Study MEDI4736 With Without Tremelimumab Versus Standard Care Chemotherapy Urothelial Cancer</brief_title>
	<detailed_description>This randomize , open-label , control , multi-center , global Phase III study determine efficacy safety MEDI4736 monotherapy MEDI4736 combination tremelimumab versus SoC ( cisplatin + gemcitabine carboplatin + gemcitabine doublet ) first-line chemotherapy treatment-naïve patient histologically cytologically document , unresectable , Stage IV transitional cell carcinoma ( transitional cell mixed transitional/non-transitional cell histology ) urothelium ( include renal pelvis , ureter , urinary bladder , urethra ) allow sufficient flexibility Investigators patient select agent reflect normal clinical practice national guideline . The patient enrol study randomize 1:1:1 receive treatment combination therapy , monotherapy , SoC ( cisplatin + gemcitabine carboplatin + gemcitabine , base cisplatin eligibility ) . Patients treat MEDI4736 MEDI4736 tremelimumab , treat SoC progressive disease ( PD ) confirm , unacceptable toxicity occur , withdrawal consent , another discontinuation criterion meet . Patients follow 2 year .</detailed_description>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Tremelimumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients histologically cytologically document , unresectable , Stage IV transitional cell carcinoma urothelium previously treat firstline chemotherapy . Patients eligible ineligible cisplatinbased chemotherapy . Cisplatin ineligibility define meet 1 follow criterion : • Creatinine clearance ( calculate measure ) &lt; 60 mL/min calculate CockcroftGault equation ( use actual body weight ) measure 24hour urine collection determination • Common Terminology Criteria Adverse Events ( CTCAE ) Grade ≥2 audiometric hearing loss • CTCAE Grade ≥2 peripheral neuropathy • New York Heart Association ≥Class III heart failure . Tumor PDL1 status , Immunohistochemical ( IHC ) assay confirm reference laboratory , must know prior randomization . Prior exposure immunemediated therapy , include limited , anti cytotoxic Tlymphocyteassociated protein 4 ( CTLA 4 ) , antiPD1 , antiPDL1 , antiPDL2 antibody , include therapeutic anticancer vaccine . Prior local intervesical chemotherapy immunotherapy allow complete least 28 day prior initiation study treatment . History allogenic organ transplantation require use immunosuppressive agent . Active prior document autoimmune inflammatory disorder . The following exception criterion : • Patients vitiligo alopecia • Patients hypothyroidism ( eg , follow Hashimoto syndrome ) stable hormone replacement • Any chronic skin condition require systemic therapy • Patients without active disease last 3 year may include consultation AstraZeneca • Patients celiac disease control diet alone may include consultation AstraZeneca . Brain metastases spinal cord compression unless patient 's condition stable steroid least 14 day prior start study treatment . Patients suspect known brain metastasis screen MRI ( prefer ) /CT , preferably IV contrast access baseline disease status . Active infection include tuberculosis , hepatitis B , hepatitis C , human immunodeficiency virus ( HIV ) . Current prior use immunosuppressive medication within 14 day first dose investigational product ( IP ) . The following exception criterion : • Intranasal , inhale , topical steroid , local steroid injection ( eg , intra articular injection ) • Systemic corticosteroid physiologic dos exceed 10 mg/day prednisone equivalent • Steroids premedication hypersensitivity reaction ( eg , CT scan premedication ) . Receipt live attenuate vaccine within 30 day prior first dose IP . Note : Patients , enrol , receive live vaccine study 30 day last dose IP .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Urothelial Cancer</keyword>
	<keyword>Phase III</keyword>
</DOC>